Amicus Therapeutics, Biotechnology Company Offering Rare Disease Therapies
Amicus Therapeutics is a biopharmaceutical company found in Cranbury, New Jersey. The company first became public in 2007 with NASDAQ trading symbol FOLD. Amicus was heavily funded by several Venture Capital firms including Canaan Partners, Radius Ventures, and New Enterprise Associates among others.
Amicus Therapeutics is mainly concerned with the treatment of rare diseases commonly referred to as lysosomal storage disorders. Most of the company’s products developments are mainly founded on Chaperone-Advanced Replacement Therapy.
In 2004, Amicus Therapeutics was specially recognized for its broad portfolio of small molecule pharmacological chaperones. Within the same period, the firm had not marketed any of its products. At the time, its most advanced candidate product was migalastat, which is a pharmacological chaperone Fabry disease treatment. Amicus Therapeutics entered into a 3-year collaboration ending 2013, with JCR Pharmaceutical and GlaxoSmithKline purposely to investigate coformulation with recombinant alpha-galactosidase. Follow Amicus Therapeutics on twitter.com.
In 2008, Amicus Therapeutics expanded its New Jersey single site to another research site found in San Diego. Even with massive financial challenges the company faced in 2009 after the termination of a multi-year collaboration the company had with The Shire, Amicus Therapeutics managed to sustain its normal operations on its way to full recovery.
Amicus Therapeutics received a total of $500,000 from The Michael J. Fox Foundation in 2010. This grant was given to support the collaborative studies conducted by Amicus Therapeutic and David Geffen School of Medicine at UCLA. Further, Amicus Therapeutics received 210,300 from Alzheimer’s Drug Discovery Foundation in support of its other collaborative pre-clinical work.
Amicus Therapeutics acquired its main competitor Callidus Biopharma. This enabled the company to gain more proprietary and intellectual properties, particularly for Pompe disease enzyme replacement treatment. Later in 2015, Amicus Therapeutics acquired Scioderm at $947 million in both stock and cash.
John F. Crowley serves as the chief executive officer and chairperson at Amicus Therapeutics. Bradley Campbell serves as the chief operating officer while William Baird serves as the chief financial officer at Amicus Therapeutics. Similarly, David Lockhart serves as the principal scientific officer in the company. Finally, Amicus Therapeutics is a pioneering biotechnology company engaged in offering advanced therapies to all rare and devastating diseases. Learn more at Seeking Alpha about Amicus Therapeutics.